Targeting All BRAF Alterations: The (Re)-Search Continues
Deepak Bhamidipati
JCO Precision Oncology
Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer
Trends in Cancer
Tumor-agnostic drug development in dMMR/MSI-H solid tumors
Esmo Open
Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine